Advaxis Inc. (NASDAQ:ADXS) was down 2.3% on Thursday . The stock traded as low as $8.44 and last traded at $8.48, with a volume of 325,778 shares trading hands. The stock had previously closed at $8.68.

Several equities research analysts have recently weighed in on ADXS shares. Jefferies Group reissued a “buy” rating on shares of Advaxis in a research report on Friday, June 10th. HC Wainwright reissued a “buy” rating on shares of Advaxis in a research report on Thursday, April 21st. Finally, FBR & Co reissued an “outperform” rating and issued a $34.00 price objective on shares of Advaxis in a research report on Tuesday, May 17th. Six investment analysts have rated the stock with a buy rating, Advaxis currently has a consensus rating of “Buy” and a consensus price target of $24.80.

The stock’s market capitalization is $295.72 million. The company has a 50-day moving average of $8.51 and a 200 day moving average of $8.17.

In other Advaxis news, CEO Daniel O’connor sold 8,237 shares of the business’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $7.51, for a total transaction of $61,859.87. Following the transaction, the chief executive officer now owns 316,661 shares of the company’s stock, valued at approximately $2,378,124.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas J. Mckearn sold 4,100 shares of the business’s stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $7.45, for a total value of $30,545.00. Following the transaction, the director now directly owns 82,120 shares in the company, valued at approximately $611,794. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Advaxis stock. Oxford Asset Management purchased a new stake in Advaxis Inc. (NASDAQ:ADXS) during the fourth quarter, Holdings Channel reports. The firm purchased 146,282 shares of the biotechnology company’s stock, valued at approximately $1,502,000. Oxford Asset Management owned 0.43% of Advaxis as of its most recent filing with the SEC.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.